ASH 2009: Bortezomib, lenalidomide, liposomal doxorubicin and dexamethasone for multiple myeloma

Share :
Published: 1 Mar 2010
Views: 8686
Prof Andrzej Jakubowiak - University of Michigan Comprehensive Cancer Center, USA
Interview by Peter Goodwin with Prof Jakubowiak discusses the RVDD trial, a 4-drug combination of bortezomib, lenalidomide, liposomal doxorubicin, and dexamethasone. Response rates seem impressive and maybe even superior to the RVD regimen, the use of bortezomib with lenalidomide and dexamethasone. Prof Jakubowiak gives his advice for the practicing physician and suggests a longer follow-up is needed to truly establish whether this 4-drug combination is an improvement over existing 3-drug combinations.